当前位置: 首页 >> 检索结果
2541. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial.
作者: .;F Van De Werf.;J Adgey.;D Ardissino.;P W Armstrong.;P Aylward.;G Barbash.;A Betriu.;A S Binbrek.;R Califf.;R Diaz.;R Fanebust.;K Fox.;C Granger.;J Heikkilä.;S Husted.;P Jansky.;A Langer.;E Lupi.;A Maseri.;J Meyer.;J Mlczoch.;D Mocceti.;D Myburgh.;A Oto.;E Paolasso.;K Pehrsson.;R Seabra-Gomes.;L Soares-Piegas.;D Sùgrue.;M Tendera.;E Topol.;P Toutouzas.;A Vahanian.;F Verheugt.;L Wallentin.;H White.
来源: Lancet. 1999年354卷9180期716-22页
Bolus fibrinolytic therapy facilitates early efficient institution of reperfusion therapy. Tenecteplase is a genetically engineered variant of alteplase with slower plasma clearance, better fibrin specificity, and high resistance to plasminogen-activator inhibitor-1. We did a double-blind, randomised, controlled trial to assess the efficacy and safety of tenecteplase compared with alteplase.
2542. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators.
来源: Lancet. 1999年354卷9180期708-15页
In unstable coronary-artery disease early invasive procedures are common, despite lack of evidence for the superiority of this approach. We compared an early invasive with a non-invasive treatment strategy in unstable coronary-artery disease.
2543. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators.
来源: Lancet. 1999年354卷9180期701-7页
Short-term treatment with subcutaneous low-molecular-mass heparin in addition to aspirin is effective in unstable coronary-artery disease. We assessed the efficacy of long-term treatment with dalteparin in patients managed with a non-invasive treatment strategy.
2546. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis.
Among 14 randomised patients with proliferative lupus nephritis, monthly intravenous immunoglobulin maintained remission over 18 months, similar to standard intravenous cyclophosphamide treatment. Pulsed immunoglobulin may be a useful alternative therapy in lupus nephritis.
2547. Activation-induced T-cell death and immune dysfunction after implantation of left-ventricular assist device.
作者: H J Ankersmit.;S Tugulea.;T Spanier.;A D Weinberg.;J H Artrip.;E M Burke.;M Flannery.;D Mancini.;E A Rose.;N M Edwards.;M C Oz.;S Itescu.
来源: Lancet. 1999年354卷9178期550-5页
Cardiac transplantation is a limited option for end-stage heart failure because of the shortage of donor organs. Left-ventricular assist devices (LVADs) are currently under investigation as permanent therapy for end-stage heart failure, but long-term successful device implantation is limited because of a high rate of serious infections. To examine the relation between LVAD-related infection and host immunity, we investigated immune responses in LVAD recipients.
2548. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.
来源: Lancet. 1999年354卷9178期533-40页
Several non-randomised trials have shown that transitional-cell carcinoma of the bladder is a moderately chemosensitive tumour. We investigated whether the addition of neoadjuvant cisplatin-based chemotherapy to radical surgery or radiotherapy would improve survival.
2549. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
作者: B J Rembacken.;A M Snelling.;P M Hawkey.;D M Chalmers.;A T Axon.
来源: Lancet. 1999年354卷9179期635-9页
Ulcerative colitis has been suggested to be caused by infection and there is circumstantial evidence linking Escherichia coli with the condition. Our aim was to find out whether the administration of a non-pathogenic strain of E. coli (Nissle 1917) was as effective as mesalazine in preventing relapse of ulcerative colitis. We also examined whether the addition of E. coli to standard medical therapy increased the chance of remission of active ulcerative colitis.
2550. Azithromycin in control of trachoma.
作者: J Schachter.;S K West.;D Mabey.;C R Dawson.;L Bobo.;R Bailey.;S Vitale.;T C Quinn.;A Sheta.;S Sallam.;H Mkocha.;D Mabey.;H Faal.
来源: Lancet. 1999年354卷9179期630-5页
Trachoma is the leading cause of preventable blindness. Programmes to prevent blindness due to trachoma are based on community-wide treatment with topical tetracycline. We assessed the potential of community-wide azithromycin treatment for trachoma control.
2555. Hormone replacement therapy and sensitive C-reactive protein concentrations in women with type-2 diabetes.
C-reactive protein concentrations as a marker of inflammation predicts vascular risk and is raised in type-2 diabetes. In a 6-month double-blind placebo controlled trial, a combination of transdermal oestradiol 80 microg with continuous oral norethisterone 1 mg significantly reduced C-reactive protein concentrations in postmenopausal women with type-2 diabetes.
2556. Zinc supplementation and bone growth in pubertal girls.
We supplemented the diets of 47 peripubertal girls with zinc (15 mg/day) or placebo for 6 weeks. Zinc supplementation increased serum zinc. Insulin-like growth factor I and biochemical markers of bone turnover did not change, albeit dietary zinc was below the reference level (in 94% of individuals).
2557. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial.
The role of oral corticosteroids in treating patients with exacerbations of chronic obstructive pulmonary disease (COPD) remains contentious. We assessed in a prospective, randomised, double-blind, placebo-controlled trial the effects of oral corticosteroid therapy in patients with exacerbations of COPD requiring hospital admission.
2558. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.
来源: Lancet. 1999年354卷9177期447-55页
There is conflicting evidence on the benefits of foods rich in vitamin E (alpha-tocopherol), n-3 polyunsaturated fatty acids (PUFA), and their pharmacological substitutes. We investigated the effects of these substances as supplements in patients who had myocardial infarction.
2560. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial.
作者: W Y Lau.;T W Leung.;S K Ho.;M Chan.;D Machin.;J Lau.;A T Chan.;W Yeo.;T S Mok.;S C Yu.;N W Leung.;P J Johnson.
来源: Lancet. 1999年353卷9155期797-801页
Resection of hepatocellular carcinoma is potentially curative, but local recurrence is common. In this prospective randomised trial, we aimed to find out if one dose of postoperative adjuvant intra-arterial iodine-131-labelled lipiodol could reduce the rate of local recurrence and increase disease-free and overall survival.
|